Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Flucytosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | THPO | P40225 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HBB | P68871 | 1/20 | 0.34 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Flucytosine SCHEMBL8160959 | 0.96 | ALDH1A1 (0.37) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| Flucytosine SCHEMBL24063 | 0.96 | — | — | |
| Flucytosine SCHEMBL3870974 | 0.94 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| Flucytosine SCHEMBL29100530 | 0.94 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| Flucytosine SCHEMBL3868918 | 0.94 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| Flucytosine SCHEMBL3869716 | 0.94 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| Flucytosine SCHEMBL28748160 | 0.94 | — | — | |
| Flucytosine SCHEMBL3871370 | 0.94 | ALDH1A1 (0.35) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| Flucytosine SCHEMBL3867430 | 0.90 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPTCYP19A1TSHR | |
| Flucytosine SCHEMBL27696081 | 0.90 | ALDH1A1 (0.33) | ALDH1A1LMNAMAPTCYP19A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130315952-A1 | ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION | DEFYRUS, INC. (CA) | 2013-11-28 | — | — | US | disclosed |
| US-8309531-B2 | Administration of interferon for prophylaxis against or treatment of pathogenic infection | DEFYRUS, INC. (CA) | 2012-11-13 | — | — | US | disclosed |
| EP-2440251-A1 | ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION | Defyrus, Inc . (CA) | 2012-04-18 | — | — | EP | disclosed |
| US-20110000480-A1 | ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION | DEFYRUS, INC. (CA) | 2011-01-06 | — | — | US | disclosed |
| WO-2010142017-A1 | ADMINISTRATION OF INTERFERON FOR PROPHYLAXIS AGAINST OR TREATMENT OF PATHOGENIC INFECTION | DEFYRUS, INC . (CA) | 2010-12-16 | — | — | WO | disclosed |
| US-6777195-B2 | THERAPEUTIC TREATMENT OF AUTOIMMUNE DISEASES; OBTAIN CELLS, INCUBATE WITH MODULATOR, MONITOR IMMUNE RESPONSE, EVALUATE FOR INFECTIONS | CYTRAN, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030198617-A1 | Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof | MELMOTTE, INC. | 2003-10-23 | — | — | US | disclosed |
| US-20020177226-A1 | Pharmaceutical dipeptide compositions and methods of use thereof: immunostimulants | CYTRAN, INC. (US) | 2002-11-28 | — | — | US | disclosed |
| US-6368788-B1 | IMMUNOSUPPRESSANTS FOR HTLV AND VIRICIDES | CYTRAN, INC. | 2002-04-09 | — | — | US | disclosed |
| US-5811399-A | Pharmaceutical dipeptide compositions and methods of use thereof: immunodepressants | CYTRAN, INC. (US) | 1998-09-22 | — | — | US | disclosed |
| US-5807830-A | ADMINISTERING GLUTAMIC ACID, TRYPTOPHAN DIPEPTIDE | CYTOVEN J.V. (US) | 1998-09-15 | — | — | US | disclosed |
| US-5770576-A | ADMINISTERING GLUTAMIC ACID-TRYPTOPHAN DIPEPTIDE TO STIMULATE BINDING FUNCTION OF T-LYMPHOCYTES | CYTRAN, INC. (US) | 1998-06-23 | — | — | US | disclosed |
| US-5728680-A | ADMINISTERING GLUTAMIC ACID-TRYPTOPHAN DIPEPTIDE; IMMUNOMODULATION | CYTOVEN J.V. (US) | 1998-03-17 | — | — | US | disclosed |
| WO-1994020063-A2 | PHARMACEUTICAL TRYPTOPHAN CONTAINING DIPEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF | CYTOVEN INTERNATIONAL N.V. (US) | 1994-09-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177226-A1 | Pharmaceutical dipeptide compositions and methods of use thereof: immunostimulants | DNPEP, ARGLU1, TSLP | ALDH1A1 4669/4885LMNA 4212/4885MAPT 3156/4885 |
| US-20030198617-A1 | Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof | AADAT, KYNU, IDO1 | ALDH1A1 4455/4885LMNA 4451/4885MAPT 1151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.